#sanofi — Public Fediverse posts

Sanofi (ENXTPA:SAN) Stops Amlitelimab In Eczema And Expands Aqemia AI Pact

Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. Sanofi…
#France #FR #Europe #EU #Sanofi #atopicdermatitis #clinicaldevelopment #dermatology #drugcandidates #generativeAI
https://www.europesays.com/france/56668/

Sanofi drops Amlitélimab in atopic dermatitis and streamlines its portfolio

As part of a strategic review of its R&D portfolio, Sanofi (-2.11%, at €74.77) has formally confirmed the…
#France #FR #Europe #EU #Sanofi #Markets
https://www.europesays.com/france/56552/

Sanofi Drops Dupixent Successor Candidate After Assessing Data – Sanofi (NASDAQ:SNY)

Two additional phase 3 studies, AQUA and ESTUARY, were anticipated to report results in the second half of…
#France #FR #Europe #EU #Sanofi #category:Biotech #category:General #category:HealthCare #category:LargeCap #category:News #CMS:WordPress #PageIsBzPro:BZ #symbol:REGN #symbol:SNY #tag:StoriesThatMatter
https://www.europesays.com/france/56540/

Press Release: Sanofi evolves its Executive Committee to support its next strategic chapter

Sanofi Winthrop Industrie Sanofi evolves its Executive Committee to support its next strategic chapter Paris, July 21, 2026.…
#France #FR #Europe #EU #Sanofi #ChiefExecutiveOfficer #ExecutiveCommittee #ExecutiveVicePresident #forward-lookingstatements #GeneralCounsel #ThomasGrenier #ThomasTriomphe
https://www.europesays.com/france/56530/

Sanofi Pulls the Plug on Amlitelimab in AD

Sanofi is halting the clinical development of amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis (AD). This decision…
#France #FR #Europe #EU #Sanofi #amlitelimab #atopicdermatitis #Rocatinlimab
https://www.europesays.com/france/56506/

Sanofi halts development of troubled immune drug in eczema

Dive Brief: Sanofi is calling it quits on an experimental eczema drug that it had seen as a…
#France #FR #Europe #EU #Sanofi
https://www.europesays.com/france/56486/

Sanofi abandons eczema drug approval efforts in another blow to OX40 class

Sanofi is discontinuing amlitelimab’s development in AD, but the Phase II study in celiac disease will continue. Credit:…
#France #FR #Europe #EU #Sanofi
https://www.europesays.com/france/56473/

Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped

Sanofi is scrapping all but one ongoing trial for an autoimmune asset that came from the $1.4 billion…
#France #FR #Europe #EU #Sanofi
https://www.europesays.com/france/56460/

Sanofi stock trades steady as vaccines and specialty medicines shape earnings outlook

Sanofi stock, tied to the French pharmaceutical group Sanofi S.A. (ISIN FR0000127771), continues to be driven by a…
#France #FR #Europe #EU #Sanofi #FR0000127771 #Vivendi
https://www.europesays.com/france/56418/

Sanofi drops eczema drug from $1.1B Kymab deal

Why it matters: Amlitelimab was the principal asset behind Sanofi’s $1.1 billion acquisition of Cambridge, UK-based Kymab in…
#France #FR #Europe #EU #Sanofi #ClinicalData
https://www.europesays.com/france/56400/

Sanofi drops development of amlitelimab in atopic dermatitis | Biotechnology

French pharma major Sanofi (Euronext: SAN) today announced the discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal…
#France #FR #Europe #EU #Sanofi
https://www.europesays.com/france/56324/

Sanofi halts amlitelimab in moderate-to-severe atopic dermatitis

Sanofi has announced it is discontinuing the clinical development of amlitelimab, an anti-OX40L ligand monoclonal antibody, in moderate-to-severe…
#France #FR #Europe #EU #Sanofi #Markets
https://www.europesays.com/france/56264/

Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances

Today, a brief rundown of news involving Arbutus BioPharma and Sanofi, as well as updates from Insmed, InnoCare…
#France #FR #Europe #EU #Sanofi
https://www.europesays.com/france/56252/

Scribe Therapeutics Files $107.2 Million IPO as Sanofi Backs Share Purchase

This article first appeared on GuruFocus. Scribe Therapeutics, a clinical-stage developer of gene therapies for heart disease, is…
#France #FR #Europe #EU #Sanofi #atheroscleroticcardiovasculardisease #biotechnologycompany #genetherapies #NasdaqGlobalMarket #Scribe #U.S.SecuritiesandExchangeCommission
https://www.europesays.com/france/56238/

Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews

Sanofi Winthrop Industrie Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews Paris,…
#France #FR #Europe #EU #Sanofi #forward-lookingstatements #regulatoryauthorities
https://www.europesays.com/france/56229/

Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews

Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews Paris, July 24, 2026.…
#France #FR #Europe #EU #Sanofi #amlitelimab #Announces #atopic #decision #dermatitis) #for #global #in #not #press #regulatory #release #Reviews #submit #to
https://www.europesays.com/france/56213/

Sanofi stock trades steady as Dupixent growth underpins outlook

Sanofi (ISIN FR0000127771) stock reflects a balance between growing specialty-care revenue and the cost of sustaining a broad…
#France #FR #Europe #EU #Sanofi #FR0000127771 #Vivendi
https://www.europesays.com/france/56092/

Common insulin pen faces supply issues amid rising demand :: WRAL.com

Some North Carolina patients with diabetes tell WRAL they’re having trouble refilling prescriptions for Lantus SoloStar insulin pens…
#France #FR #Europe #EU #Sanofi #diabetes #health #insulin
https://www.europesays.com/france/56011/

Sanofi insulin product, Lantus Solostar pen, reported in short supply

People with diabetes who use a popular long-acting insulin pen made by Sanofi have had to become pharmacy…
#France #FR #Europe #EU #Sanofi #chronicdiseases #diabetes #Pharmaceuticals #STAT+
https://www.europesays.com/france/55886/

The Escalator: Roche, Sanofi, Merck and more

New hires: 2026 MM+M Agency 100 honoree Digitas Health hired Mecca Scott as EVP of project management and…
#France #FR #Europe #EU #Sanofi
https://www.europesays.com/france/55832/

Sanofi’s Executive Leadership Reshuffle: The Key Changes

Discussing his new role on LinkedIn, Paulo writes, “I am incredibly excited to be joining Belén Garijo and…
#France #FR #Europe #EU #Sanofi
https://www.europesays.com/france/55811/

Sanofi’s New CEO Has A Simple To-Do List: Deals Or Buybacks

t next wave to come from commercial-stage or late-stage assets – drugs close to launch – because early…
#France #FR #Europe #EU #Sanofi
https://www.europesays.com/france/55636/

Sanofi India Whole Time Director and CFO Rachid Ayari to step down on September 30

Sanofi India Ltd. has announced that Whole Time Director, Chief Financial Officer and Key Managerial Personnel Rachid Ayari…
#France #FR #Europe #EU #Sanofi
https://www.europesays.com/france/55618/

Sanofi Completes Dosing in Phase 1 Trial of ‘Dupixent’ Utilizing Alteogen’s Technology

Sanofi’s ‘Dupixent’ (ingredient: dupilumab), which utilizes Alteogen’s subcutaneous (SC) injection platform technology, has completed dosing for participants in…
#France #FR #Europe #EU #Sanofi #economic #Issue #Korea #News #Newspaper #Politics #Society #SouthKorea #TheAsiaBusinessDaily
https://www.europesays.com/france/55602/

Sanofi India CFO Rachid Ayari to step down from key roles effective 30 Sept 2026 | Capital Market News

Last Updated : Jul 23 2026 | 12:16 PM IST Sanofi India announced that Rachid Ayari will step…
#France #FR #Europe #EU #Sanofi #CAC40 #CFO #chieffinancialofficer #ChiefFinancialOfficer(CFO) #GenericPharmaceuticals #pharmaceuticalproducts #Pharmaceuticals(NEC) #RachidAyari #RiskManagementCommittee #SanofiGroup #SanofiIndia #WholeTimeDirector
https://www.europesays.com/france/55583/

Sanofi India CFO Rachid Ayari To Leave Position On September 30, 2026

Market snapshot: Sanofi India Limited has announced that Whole-Time Director and Chief Financial Officer (CFO) Rachid Ayari will…
#France #FR #Europe #EU #Sanofi
https://www.europesays.com/france/55561/

Amundi discloses 5.65% beneficial stake in Sanofi | SNY SEC Filing

schemaVersion: CUSIP Number(s): 80105N105 1Names of Reporting Persons AMUNDI 2Check the appropriate box if a member of a…
#France #FR #Europe #EU #Sanofi #5.65percent #651 #68 #904shares #Amundi #beneficialownership #FCPE #institutionalinvestor #Schedule13Gamendment #SNY #votingpower
https://www.europesays.com/france/55256/

Sanofi stock steadies as vaccines and specialty care support earnings

Sanofi stock offers investors exposure to a diversified global healthcare group with a long-established presence in prescription medicines,…
#France #FR #Europe #EU #Sanofi #FR0000120578
https://www.europesays.com/france/55194/

Sanofi reshapes executive team as it prepares next phase of strategy

Sanofi (Euronext: SAN; Nasdaq: SNY) has announced changes to its executive committee, as the French pharma major streamlines…
#France #FR #Europe #EU #Sanofi
https://www.europesays.com/france/55111/

Sanofi stock trades steady as recent earnings and pipeline updates frame valuation

Sanofi stock, tied to the French pharmaceutical group Sanofi S.A. (ISIN FR0000127771), continues to be underpinned by its…
#France #FR #Europe #EU #Sanofi #FR0000127771 #Vivendi
https://www.europesays.com/france/55093/

Sanofi Restructures Its Executive Committee Effective September 1, 2026, with Two Executives Departing

On July 21, Sanofi announced changes to its executive committee, effective September 1, 2026. This reorganization focuses power…
#France #FR #Europe #EU #Sanofi
https://www.europesays.com/france/55010/

Sanofi is building its own AI ecosystem to give the French pharma giant an edge

In the early days of the generative artificial intelligence boom, Sanofi’s chief digital officer, Emmanuel Frenehard, wasn’t particularly…
#France #FR #Europe #EU #Sanofi #agentic #AIchatbot #ElementumAI #EmmanuelFrenehard #Frenehard
https://www.europesays.com/france/54975/

Press Release: Sanofi evolves its Executive Committee to

Sanofi evolves its Executive Committee to support its next strategic chapter Paris, July 21, 2026. Sanofi today announced…
#France #FR #Europe #EU #Sanofi #ParisStockExchange:SAN #SanofiWinthropIndustrie
https://www.europesays.com/france/54702/

Sanofi publicly reprimanded after UK code breaches over Beyfortus promotion

French pharma major Sanofi (Euronext Paris: SAN) has been publicly reprimanded after the UK Prescription Medicines Code of…
#France #FR #Europe #EU #Sanofi
https://www.europesays.com/france/54684/

Sanofi stock trades steady as vaccine and specialty care revenue underpin valuation

Sanofi stock, tied to the French healthcare group Sanofi S.A. (ISIN FR0000127771), stands on a large global footprint…
#France #FR #Europe #EU #Sanofi #FR0000127771 #Vivendi
https://www.europesays.com/france/54543/

Sanofi stock falls after a quarterly revenue update

Sanofi (FR0000127771) remains a large-cap European health-care name, but the latest verified search results available in this call…
#France #FR #Europe #EU #Sanofi #FR0000127771 #Vivendi
https://www.europesays.com/france/54523/

Sanofi stock trades steadily as Dupixent growth supports earnings outlook

Sanofi stock is trading steadily as investors weigh the French pharmaceutical group’s (ISIN FR0000120578) expanding specialty medicines portfolio…
#France #FR #Europe #EU #Sanofi #FR0000120578
https://www.europesays.com/france/54507/

Lobbying Update: $920,000 of SANOFI US SERVICES INC lobbying was just disclosed

$920,000 of SANOFI US SERVICES INC lobbying was just disclosed, from Q2 of 2026, in a new Lobbying…
#France #FR #Europe #EU #Sanofi
https://www.europesays.com/france/54331/

Sanofi stock trades steadily as oncology and immunology pipeline shapes outlook

Sanofi stock offers investors exposure to a large, diversified European pharmaceutical group whose earnings and cash flows are…
#France #FR #Europe #EU #Sanofi #FR0000127771 #Vivendi
https://www.europesays.com/france/54156/

Sanofi stock trades steady as vaccines and specialty care drive earnings momentum

Sanofi stock is supported by earnings momentum as the French healthcare group Sanofi S.A. (ISIN FR0000127771) leans on…
#France #FR #Europe #EU #Sanofi #FR0000127771 #Vivendi
https://www.europesays.com/france/54093/

https://www.europesays.com/ch/105683/ Novartis Earnings Preview: Can New Medicines Offset Generic Pressure and Growing U.S. Pricing Risks? #AstraZeneca #avidi #Novartis #NovartisAG #NovoNordisk #RocheHoldingAG #Sanofi #stocks #weekly #YahooFeed

Cancer Therapy Market is Going to Boom: New Report Reveals Massive Growth Potential 2026-2033

Cancer Therapy Market The cancer therapy market is estimated to be valued at USD 260.52 Bn in 2026…
#France #FR #Europe #EU #Sanofi #CancerTherapyMarket
https://www.europesays.com/france/53993/

Sanofi stock steadies as Dupixent growth supports earnings outlook

Sanofi (ISIN FR0000120578) stock is supported by a sizeable earnings base from 2025 and by continued growth of…
#France #FR #Europe #EU #Sanofi #FR0000120578
https://www.europesays.com/france/53768/

Sanofi stock trades steadily as vaccines and specialty care support earnings

Sanofi stock represents one of Europes larger global pharmaceutical positions, with the French healthcare group (ISIN FR0000127771) combining…
#France #FR #Europe #EU #Sanofi #FR0000127771 #Vivendi
https://www.europesays.com/france/53759/

ADEL Nears IPO on Sanofi Deal, Eyes New Tech Transfer Within 1-2 Years

ADEL CEO Yoon Seung-yong explains the Alzheimer’s disease drug candidate “ADEL-Y01” at the company’s headquarters in Gangdong-gu, Seoul,…
#France #FR #Europe #EU #Sanofi #ADEL #ADEL-Y01 #Alzheimer'sdiseasetreatment #ApoE4antibody #blood-brainbarrierplatform #KOSDAQIPO #technologytransfer
https://www.europesays.com/france/53734/

Sanofi stock trades steady as recent earnings and pipeline shape outlook

Sanofi stock, tied to the French healthcare group Sanofi S.A. (ISIN FR0000127771), reflects a balance between stable revenue…
#France #FR #Europe #EU #Sanofi #FR0000127771 #Vivendi
https://www.europesays.com/france/53668/

Weil Advises Sanofi in its $2.2 Billion Acquisition of Dynavax

Weil is advising Sanofi in its agreement to acquire Dynavax Technologies Corporation, a publicly traded vacc…
#France #FR #Europe #EU #Sanofi #Antitrust #AntitrustCartelandInvestigations #AntitrustLitigation #capitalmarkets #D.C. #ExecutiveCompensation&Benefits #Mergers&Acquisitions #NewYork #Privacy&Cybersecurity #realestate #RegulatoryTransactions #Tax #Technology&IPTransactions #Washington
https://www.europesays.com/france/53656/

Sanofi stock holds steady as investors await new data

Sanofi stock remains centered on the companys latest disclosed financial base, with the French group (ISIN FR0000120578) reporting…
#France #FR #Europe #EU #Sanofi #FR0000120578
https://www.europesays.com/france/53652/

Devika Gupta Joins Sanofi as Head of Value for Healthcare Systems & Economics

Morristown, New Jersey, United States, July 2026 — Sanofi has appointed Devika Gupta as Head of Value for…
#France #FR #Europe #EU #Sanofi
https://www.europesays.com/france/53559/

Sanofi stock trades steady as latest quarterly results highlight vaccine and specialty care momentum

Sanofi stock offers investors a picture shaped by recent earnings metrics rather than intraday swings. The French healthcare…
#France #FR #Europe #EU #Sanofi #FR0000127771 #Vivendi
https://www.europesays.com/france/53508/